Vericel (VCEL) Profit After Tax (2010 - 2026)
Vericel (VCEL) posted Profit After Tax of $2.2 million for Q2 2026, up 135.0% sequentially from -$6.3 million in Q1 2026, and up 498.92% YoY from $368332.7 in Q2 2025.
Analysis
Vericel (VCEL) Profit After Tax (2010 - 2026) Analysis & Trends
Vericel has reported Profit After Tax for 17 years, with the latest figure at $2.2 million in Q2 2026.
- Quarterly Profit After Tax rose 498.92% year-over-year to $2.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $24.2 million (up 240.8% YoY) and the FY2025 annual result came in at $16.5 million, up 59.41% from the prior year.
- Profit After Tax grew to $2.2 million in Q2 2026 per VCEL's latest filing, from -$6.3 million in the prior quarter.
- Over five years, Profit After Tax peaked at $23.2 million in Q4 2025 and troughed at -$11.2 million in Q1 2025.
- A 5-year average of $160722.2 and a median of -$3.8 million in 2023 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 663.15% in 2025, down 191.2% in 2025.
- Over 5 years, Profit After Tax stood at $5.9 million in 2022, then surged by 119.4% to $13.0 million in 2023, then soared by 52.44% to $19.8 million in 2024, then grew by 17.35% to $23.2 million in 2025, then tumbled by 90.51% to $2.2 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $2.2 million, -$6.3 million, and $23.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 2.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | -6.30 Mn |
| Dec 31, 2025 | 23.24 Mn |
| Sep 30, 2025 | 5.07 Mn |
| Jun 30, 2025 | -553,000.00 |
| Mar 31, 2025 | -11.25 Mn |
| Dec 31, 2024 | 19.81 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -4.68 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 12.99 Mn |
| Sep 30, 2023 | -3.66 Mn |
| Jun 30, 2023 | -5.02 Mn |
| Mar 31, 2023 | -7.50 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.54 Mn |
| Sep 30, 2021 | -4.93 Mn |